



Q Search Brand/Products ...

ADVANCED SEARCH

## **Quick Links**

**MY FORECASTS** 

TRENDING FORECASTS

**ALERTS** 

**CREATE NEW FORECAST** 

**UPLOAD EXISTING FORECAST** 





Q Irinotecan Injection

### Search Results



NO FORECASTS FOUND FOR THE GIVEN SEARCH TERM

CREATE NEW FORECAST





Q asp

### Search Results

# 2 FORECASTS FOUND FOR THE GIVEN SEARCH TERM

<b>ASP</b> IRIN	>
<b>ASP</b> ARTAME	>


CREATE NEW FORECAST





# New Post-Market Forecast - Hierarchy

Product															
NAME	NAME Irinotecan Injection														
Strength															
40mg/2ml	100mg/5ml	20mg/ml													
Pack Size ( x1 v	vial)														
2ml	5ml	15ml													



HIERARCHY





### New Post-Market Forecast - General Information

**TLD** 

05 - September - 2016

**PROJECT ID** 

3568

# OF COMPETITORS

7

NAMES OF COMPETITORS

APP, Hospira, Heritage, Teva, Sandoz, Sagent, Westward

TARGET MARKET SHARE

14 %

MARKET SHARE TREND

Constant

Growing at 3 % Falling at -- %

MARKET SHARE REVISION PERIOD

6 months

SUBSTITUTION RATE

88

SUBSTITUTION GROWTH RATE

0.20

%

**ANNUAL PRICE EROSION** 

10

%

HEIRARCHY GENERAL INFO







**CURRENT MARKET SIZE** 

IMS version/dated

**PRICING** 

Price Rx version/dated

COGS

SAP

**FORECAST** 

Project based on current mkt. size

**COMPETITOR INFO** 


FDA Orange Book

**VIEW ALL SOURCES** 









### **FORECAST**

Project based on current mkt. size

**COMPETITOR INFO** 

FDA Orange Book

**VIEW ALL SOURCES** 







#### **CURRENT MARKET SIZE**

IMS version/dated

### **PRICING**

File\_Price\_2017\_v1 version/dated

PRICERX

FILE\_PRICE\_2017\_V1 √

FILE\_PRICE\_2016\_V9

### **FORECAST**

Project based on current mkt. size

### **COMPETITOR INFO**

FDA Orange Book

**VIEW ALL SOURCES** 







### **CURRENT MARKET SIZE**

IMS version/dated

### **PRICING**


File\_Price\_2017\_v1 version/dated

COGS

SAP

### **FORECAST**

Project based on current mkt. size 🗸



**VIEW ALL SOURCES** 







### **CURRENT MARKET SIZE**

IPD version/dated

### **PRICING**

File\_Price\_2017\_v1 version/dated

COGS

SAP

### **FORECAST**

Project based on current mkt. size

### **COMPETITOR INFO**

FDA ORANGE BOOK

IMS √

**VIEW ALL SOURCES** 







### New Post-Market Forecast - Units

	Strength	Pack Size	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17	Sep-17	Oct-17	Total
Trend			0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%	
Sub Rate			100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	
APO Market Share			10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	
Total Units	40mg/2mL	2mL (x1 Vial)	31,783	31,863	31,942	32,022	32,102	32,182	32,263	32,343	32,424	32,505	32,587	32,668	386,685
Generic Units			31,783	31,863	31,942	32,022	32,102	32,182	32,263	32,343	32,424	32,505	32,587	32,668	386,685
APO Units			3,178	3,186	3,194	3,202	3,210	3,218	3,226	3,234	3,242	3,251	3,259	3,267	38,669
APO Pipeline															
Total Units	100mg/5mL	5mL (x1 Vial)	83,828	84,038	84,248	84,458	84,669	84,881	85,093	85,306	85,519	85,733	85,948	86,162	1,019,884
Generic Units			83,828	84,038	84,248	84,458	84,669	84,881	85,093	85,306	85,519	85,733	85,948	86,162	1,019,884
APO Units			8,383	8,404	8,425	8,446	8,467	8,488	8,509	8,531	8,552	8,573	8,595	8,616	101,988
APO Pipeline															

**EXPORT TO EXCEL** 

**RE-GENERATE** 

#### Products Affected - Description

#### 5% DEXTROSE INJECTION, BBRAUN

250 mL PVC/DEHP-free bag, 1 count (NDC 00264-7510-20) 500 mL PVC/DEHP-free bag, 1 count (NDC 00264-7510-10) 1000 mL PVC/DEHP-free bag, 1 count (NDC 00264-7510-00)

#### 5% DEXTROSE INJECTION, BAXTER

250 mL PVC/DEHP-free bag, 40 count (NDC 00338-6346-02) 500 mL PVC/DEHP-free bag, 1 count (NDC 00338-6346-03)

#### 5% DEXTROSE INJECTION, ICU MEDICAL

250 mL PVC/DEHP-free bag, 24 count (NDC 00409-7922-25)

#### Available Products

#### 5% DEXTROSE INJECTION, ICU MEDICAL

100 mL PVC/DEHP-free bag, 60 count (NDC 00409-7923-11)

#### 5% DEXTROSE, ICU MEDICAL

50 mL PVC/DEHP-free bag, 60 count (NDC 00409-7923-06)

#### Estimated Resupply Dates

BBraun has 5% dextrose 250 mL, 500 mL, and 1,000 mL PVC/DEHP-free bags on allocation.

Baxter has 5% dextrose 250 mL and 500 mL PVC/DEHP-free bags on back order and the company cannot estimate a release date.

ICU Medical has 5% dextrose 250 mL PVC/DEHP-free bags on intermittent back order and the company is releasing product as it becomes available.

UNITS FINANCIALS CONTINUE TO FINANCIALS





### $\leftarrow$

### New Post-Market Forecast - Financials

Strength	Pack Size		Nov-16	D	ec-16	J	an-17	·	Feb-17	Mar-17	Apr-17	May-17	Jun-17	Jul-17	Aug-17	Sep-17	Oct-17	Tot	al	Ave	rage Pri
40mg/2mL	2mL (x1 Vial)	Finished Goods	3,178	- 1	,186		3,194		3,202	3,210	3,218	3,226	3,234	3,242	3,251	3,259	3,267		38,669		
		ASP\$	\$ 5.22	\$	5.20	\$	5.17	\$	5.15	\$ 5.12	\$ 5.09	\$ 5.07	\$ 5.04	\$ 5.02	\$ 4.99	\$ 4.97	\$ 4.94			\$	5.08
		Gross Revenue	\$ 16,603	\$ 16	,561	\$ 16	5,520	\$ 1	6,478	\$ 16,437	\$ 16,395	\$ 16,354	\$ 16,313	\$ 16,272	\$ 16,231	\$ 16,190	\$ 16,150	\$	196,504		
		SR&A @ 15%	\$ 2,490	\$ :	,484	\$ :	2,478	\$	2,472	\$ 2,465	\$ 2,459	\$ 2,453	\$ 2,447	\$ 2,441	\$ 2,435	\$ 2,429	\$ 2,422	\$	29,476		
		Net Revenue	\$ 14,112	\$ 14	,077	\$ 14	1,042	\$ 1	4,006	\$ 13,971	\$ 13,936	\$ 13,901	\$ 13,866	\$ 13,831	\$ 13,797	\$ 13,762	\$ 13,727	\$	167,028		
		COGs	\$ 3.60	\$	3.60	\$	3.60	\$	3.60	\$ 3.60		1111									
		Extended COGs	\$ 11,442	\$ 11	,471	\$ 11	1,499	\$ 1	1,528	\$ 11,557	\$ 11,586	\$ 11,615	\$ 11,644	\$ 11,673	\$ 11,702	\$ 11,731	\$ 11,761	\$	139,207		
	10	Net Margin	\$ 2,671	\$ 2	,606	\$ 2	2,542	\$	2,478	\$ 2,414	\$ 2,350	\$ 2,286	\$ 2,222	\$ 2,158	\$ 2,095	\$ 2,031	\$ 1,967	\$	27,822		
100mg/5mL	5mL (x1 Vial)	Finished Goods	8,383		,404		8,425	9	8,446	8,467	8,488	8,509	8,531	8,552	8,573	8,595	8,616		101,988		
		ASP\$	\$ 11.32	\$ :	1.26	\$	11.20	\$	11.15	\$ 11.09	\$ 11.04	\$ 10.98	\$ 10.93	\$ 10.87	\$ 10.82	\$ 10.76	\$ 10.71			\$	11.01
		Gross Revenue	\$ 94,859	\$ 94	,621	\$ 94	1,383	\$ 9	4,146	\$ 93,909	\$ 93,673	\$ 93,438	\$ 93,203	\$ 92,969	\$ 92,735	\$ 92,502	\$ 92,270	\$	1,122,708		
		SR&A @ 15%	\$ 14,229	\$ 14	,193	\$ 14	4,157	\$ 1	4,122	\$ 14,086	\$ 14,051	\$ 14,016	\$ 13,980	\$ 13,945	\$ 13,910	\$ 13,875	\$ 13,840	\$	168,406		
		Net Revenue	\$ 80,630	\$ 80	,428	\$ 80	),225	\$ 8	0,024	\$ 79,823	\$ 79,622	\$ 79,422	\$ 79,223	\$ 79,024	\$ 78,825	\$ 78,627	\$ 78,429	\$	954,302		
		COGs	\$ 6.60	\$	6.60	\$	6.60	\$	6.60	\$ 6.60											
		Extended COGs	\$ 55,327	\$ 55	,465	\$ 55	5,604	\$ 5	5,743	\$ 55,882	\$ 56,022	\$ 56,162	\$ 56,302	\$ 56,443	\$ 56,584	\$ 56,725	\$ 56,867	\$	673,124		
		Net Margin	\$ 25,304	\$ 24	,963	\$ 24	1,622	\$ 2	4,281	\$ 23,941	\$ 23,601	\$ 23,261	\$ 22,921	\$ 22,581	\$ 22,241	\$ 21,902	\$ 21,562	\$	281,178		
20mg/mL	15mL (x1 Via	Finished Goods	-		-		9 (		-	-	-	-	-	-	-	-	-		-		
		ASP\$	\$ 	\$	-	\$	5	\$	5	\$ -	\$ 	\$ 	\$ -	\$ -	\$	\$ 	\$ 			\$	- 5
		Gross Revenue	\$ -	\$	-	\$	-	\$		\$ -	\$	•									
		SR&A @ 15%	\$ -	\$	-	\$	-	\$		\$ -	\$ - 1	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$			
		Net Revenue	\$ -	\$		\$	-	\$	-	\$ -	\$	-									
		COGs	\$	\$	-	\$	5	\$	5	\$ (5)	\$ (5)	\$	\$	\$ 	\$ [7]	\$	\$ (5)				
		Extended COGs	\$ -	\$	-	\$	-	\$	*	\$ -	\$										
		Net Margin	\$ 	\$		\$		\$	20	\$ 0.0	\$ -	\$ 	\$ · ·	\$ -	\$ 0.0	\$ - 0	\$ 	\$			

**EXPORT TO EXCEL**